Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.03−0.03 (-2.83%)
Close on Nov 18, 2026Market cap $103.35MP/E –Yield –
Cellectis net income
Net income is the profit left for shareholders after every expense, interest and tax.
Cellectis's net income for the twelve months ending Dec 31, 2023 was -$101.06M. For fiscal 2025 it was -$67.59M. The highest annual figure on record is -$22.80M in fiscal 2015.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$67.59M | – |
| FY2024 | Dec 31, 2024 | -$36.76M | – |
| FY2023 | Dec 31, 2023 | -$101.06M | – |
| FY2022 | Dec 31, 2022 | -$106.14M | – |
| FY2021 | Dec 31, 2021 | -$114.20M | – |
| FY2020 | Dec 31, 2020 | -$81.07M | – |
| FY2019 | Dec 31, 2019 | -$102.09M | – |
| FY2018 | Dec 31, 2018 | -$78.69M | – |
| FY2017 | Dec 31, 2017 | -$99.37M | – |
| FY2016 | Dec 31, 2016 | -$67.26M | – |
| FY2015 | Dec 31, 2015 | -$22.80M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -$23.74M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$41.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.48M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$39.92M | – |
| Q2 FY2020 | Jun 30, 2020 | -$32.26M | – |
| Q2 FY2019 | Jun 30, 2019 | -$33.45M | – |
See a number that looks wrong?